Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Common Equity (2021 - 2026)

Nuvectis Pharma has reported Common Equity over the past 6 years, most recently at $14.2 million for Q1 2026.

  • Quarterly results put Common Equity at $14.2 million for Q1 2026, down 32.14% from a year ago — trailing twelve months through Mar 2026 was $14.2 million (down 32.14% YoY), and the annual figure for FY2025 was $18.4 million, up 89.57%.
  • Common Equity reached $14.2 million in Q1 2026 per NVCT's latest filing, down from $18.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $24.0 million in Q3 2025 and bottomed at $9.7 million in Q4 2024.
  • Median Common Equity over the past 5 years was $14.2 million (2026), compared with a mean of $15.5 million.
  • The largest annual shift saw Common Equity skyrocketed 44218.18% in 2022 before it crashed 38.38% in 2024.
  • Over 5 years, Common Equity stood at $14.2 million in 2022, then fell by 14.19% to $12.2 million in 2023, then dropped by 20.39% to $9.7 million in 2024, then soared by 89.57% to $18.4 million in 2025, then fell by 22.77% to $14.2 million in 2026.
  • Business Quant data shows Common Equity for NVCT at $14.2 million in Q1 2026, $18.4 million in Q4 2025, and $24.0 million in Q3 2025.